Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 57 for Clinical Genomics

Edit search filters
  1. A Study to Evaluate Myeloma-Developing Regimens Using Genomics (MyDRUG)

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. Mayo Clinic Health TAPESTRY: Use of Genomic Sequencing in Clinical Practice

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. A Study to Investigate RO7248824 in Participants With Angelman Syndrome

    Rochester, MN

  4. A Phase I study of Epalrestat Therapy in a Single Patient with Phosphomannomutase Deficiency (PMM2-CDG)

    Rochester, MN

  5. A Study of the Safety and Effectiveness of (+) Epicatechin for Treating Patients with Friedreich's Ataxia

    Rochester, MN

  6. Myocardial Infarction Genes (MI-GENES) Study

    Rochester, MN

  7. Gemini Study to Evaluate the Integration of Cancer Genetic Testing into a Cancer Clinical Practice at Mayo Clinic at Arizona

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  8. Impact of Estradiol Addback

    Rochester, MN

  9. A Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

    Rochester, MN

  10. A Study to Assess the MEK Inhibitor Mirdametinib (PD-0325901) in Patients with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer